IL-18BPを分泌し,潰瘍性大腸炎のシナギスティック療法のための二重単原子触媒を装備したプロバイオティクスの設計
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。この研究は,潰瘍性大腸炎 (UC) の治療のための新しいバイオナノプラットフォームを導入します. 合成されたプロバイオティックは 酸化ストレスを軽減し 炎症を調節し 腸内微生物のバランスを回復し 腸内ホメオスタシスを改善します
科学分野
- 胃腸内科
- ナノテクノロジー
- 微生物学
背景
- 潰瘍性大腸炎 (UC) は,酸化ストレスと腸内不活性症によって特徴付けられます.
- 現在の治療法では これらの多面的な病理的側面を 同時に対処することが困難です
研究 の 目的
- 統合されたバイオナノプラットフォームを開発し,UC治療の連携を図る.
- 双重単原子触媒 (DAC) と,改良されたプロバイオティクスを組み合わせて,治療効果を高める.
主な方法
- IL-18BPを発現させるためのEscherichia coli* Nissle 1917 (EcN) を設計した.
- エンジニアリングされたECNと結合したDACは,DEIのバイオナノプラットフォームを形成します.
- デクストラン硫酸ナトリウム誘発大腸炎のマウスモデルに経口投与
主要な成果
- DEIは反応性酸素種 (ROS) を効果的に除去し,炎症誘発性サイトカインを中和しました.
- バイオナノプラットフォームは,設計されたECNのコロニー化と治療効果を向上させました.
- DEIは大腸炎の症状を和らげ 炎症を軽減し 腸内微生物のバランスを回復しました
結論
- 多機能のDEIバイオプラットフォームはUC治療のための有望なシナジスティック戦略を提供します.
- このアプローチはROSスキャビング,免疫調節,微生物群の回復を統合しています.
- バイオナノプラットフォームは,臨床前の大腸炎のモデルで腸内ホメオスタシスを促進します.
関連する概念動画
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Strictureplasty
Proctocolectomy or total colectomy with ileostomy
Restorative proctocolectomy with Ileal pouch-anal anastomosis
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...